Blog Archive

Tuesday, August 24, 2021

08-24-2021-1018 - Hydroxycamptothecin mediates antiproliferative effects through apoptosis and autophagy in A549 cells

 2018 May; 15(5): 6322–6328. 
Published online 2018 Feb 22. doi: 10.3892/ol.2018.8107
PMCID: PMC5876437
PMID: 29616109

Hydroxycamptothecin mediates antiproliferative effects through apoptosis and autophagy in A549 cells

Author information Article notes Copyright and License information Disclaimer

 Hydroxycamptothecin (HCPT) represents a new generation of anticancer drugs, with almost no side effects when used for the treatment of a number of types of cancer. Autophagy is becoming recognized as an important biological mechanism in human cancer, including lung cancer. However, the involvement of autophagy in the antiproliferative effects of HCPT on lung cancer remains unclear. In the present study, A549 cells, an accepted model of non-small cell lung cancer (NSCLC) cells, were employed. It was demonstrated that HCPT was able to suppress proliferation and induce apoptosis and autophagy in A549 cells. The molecular mechanism underlying HCPT-induced cell death was attributed to apoptosis and autophagy. Furthermore, it was demonstrated that an autophagy inhibitor, 3-methyladenine, accelerated HCPT-induced cell death in A549 cells. The results of the present study may lead to a deeper understanding of the molecular mechanism by which HCPT regulates NSCLC A549 cells. These results highlight the potential use of autophagy inhibitors in combination with traditional chemotherapy drugs for the treatment of lung cancer.

Keywords: lung cancer, non-small cell lung cancer, autophagy, apoptosis, autophagy inhibitor, hydroxycamptothecin

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5876437/

No comments:

Post a Comment